Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Feigal, Tunis To Present At HHS Reg Reform Panel On FDA/CMS Partnerships

This article was originally published in The Gray Sheet

Executive Summary

Collaborative opportunities between FDA and the Centers for Medicare & Medicare Services for approving new technologies will be explored during the upcoming 1HHS Advisory Committee on Regulatory Reform's public hearing in Minneapolis

You may also be interested in...



FDA Should Turn Over AE Analysis Criteria To Firms – Boston Scientific Exec

Much of the analysis of device-related adverse event reports currently handled by FDA could be completed by device manufacturers if the agency provided the criteria, according to Boston Scientific Manager for Quality and Regulatory Compliance Kristin Johnson

FDA Should Turn Over AE Analysis Criteria To Firms – Boston Scientific Exec

Much of the analysis of device-related adverse event reports currently handled by FDA could be completed by device manufacturers if the agency provided the criteria, according to Boston Scientific Manager for Quality and Regulatory Compliance Kristin Johnson

Medicare Local, National Coverage Process Will Be Topic Of MTLF Meeting

Medtronic is sponsoring a Medical Technology Leadership Forum on Medicare local and national coverage decisions June 28

Related Content

Latest News
See All
UsernamePublicRestriction

Register

MT016654

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel